Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G 165 versus GRISEOFULVIN ULTRAMICROSIZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G 165 versus GRISEOFULVIN ULTRAMICROSIZE.
FULVICIN P/G 165 vs GRISEOFULVIN, ULTRAMICROSIZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Griseofulvin binds to and disrupts microtubule function by inhibiting spindle formation and mitosis in dermatophytes, leading to inhibition of fungal cell division.
Binds to tubulin, disrupting microtubule function and inhibiting fungal cell mitosis; deposited in keratin precursor cells, making keratin resistant to fungal invasion.
165 mg orally once daily.
250-375 mg orally once daily or 500-750 mg orally once daily for severe infections.
None Documented
None Documented
Terminal elimination half-life is approximately 9-24 hours; dependent on formulation and absorption rate. Steady-state achieved within 4-5 days.
9-24 hours (mean 15 hours); prolonged in liver disease.
Primarily renal excretion of metabolites; <1% excreted unchanged. Biliary/fecal elimination accounts for ~30% of metabolites.
Renal (<1% unchanged); fecal (36% as metabolites); tissue deposition may persist for weeks.
Category C
Category D/X
Antifungal
Antifungal